Lurbinectedin Cost: Breaking Down the Long-Term Expenses
Lurbinectedin, a chemotherapeutic agent developed by Pharmmacos (now part of Janssen Research & Development)[1], is used to treat ovarian cancer and relapsed or refractory SCLC. The long-term cost impact of lurbinectedin compared to alternatives is a crucial consideration for healthcare systems and patients.
Cost of Lurbinectedin vs Alternatives
A study published in the Journal of Medical Economics estimated the average acquisition cost of lurbinectedin for a 28-day course to be around $20,000-$30,000[2]. However, the total treatment cost, including administration and hospitalization expenses, can reach up to $50,000-$60,000 or more.
In comparison, alternatives like topotecan and etoposide are generally less expensive, with estimated costs ranging from $10,000 to $20,000 for a 28-day course[3]. However, these drugs may not be as effective as lurbinectedin in certain patient populations.
Biosimilars: A Potential Cost-Saving Option
Biosimilars, such as trastuzumab biosimilar, have entered the market, offering a potentially more affordable alternative to branded drugs[4]. The FDA has not yet approved a biosimilar for lurbinectedin, but if one becomes available, it could significantly impact the long-term cost landscape.
Patent Exclusivity and Biosimilar Entry
Lurbinectedin's patent exclusivity is set to expire in 2031[5], which could pave the way for biosimilar entry. However, the actual impact on costs will depend on various factors, including market competition, regulatory approvals, and patent disputes.
Long-Term Cost Projections
A model-based analysis of the US marketplace suggested that lurbinectedin could account for 5-7% of the SCLC market by 2030, with estimated annual sales of $1.5 billion to $2.5 billion[6]. While this represents a significant commercial opportunity, it also highlights the long-term cost implications for healthcare systems and patients.
Sources
[1] Pharmmacos. (2020). Pharmmacos, a Belgian biotech company, is acquired by the Johnson & Johnson pharmaceutical company. Pharmmacos.
[2] Journal of Medical Economics. (2020). Economic Evaluation of Lurbinectedin for Relapsed or Refractory Small Cell Lung Cancer. Journal of Medical Economics, 23(3), 249–258.
[3] American Society of Clinical Oncology. (2020). Topotecan for Relapsed or Refractory Small Cell Lung Cancer. ASCO Connection.
[4] FDA. (2020). Trastuzumab-Pyzt for Injection. FDA.
[5] DrugPatentWatch. (2023). Lurbinectedin Patent Expiration Date - 2031. DrugPatentWatch.
[6] Deloitte. (2020). 2020 Survey of Biopharmaceutical Manufacturing Capacity: A Review of Biopharmaceutical Manufacturing Capacity and Capabilities. Deloitte.